Clinical Trial Update: CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 clinical trial investigates CAR19BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms and lymphomas/leukemias with plasmacytic d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR19BCMA CAR-T cells

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation | EARLY_Phase 1 | Status: NOT_YET_RECRUITING